Double-Dose Firmonertinib Boosts EGFR L858R Lung Cancer Treatment
A groundbreaking advancement in the fight against non-small-cell lung cancer (NSCLC) has emerged from a recent multicenter phase II study ...
Tag: Based on the content describing a phase II trial on double-dose firmonertinib for EGFR L858R-mutant NSCLC
